Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLC

H. Jack West, MD
Published: Thursday, Apr 19, 2018



H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation–positive non–small cell lung cancer (NSCLC).


H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation–positive non–small cell lung cancer (NSCLC).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x